MannKind: Pediatric Expansion, Improved Dosing, and Pipeline Diversification Drive Buy Rating on Afrezza Growth Potential

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on MannKind, with a price target of $10.00.

Yun Zhong has given his Buy rating due to a combination of factors tied to Afrezza’s growing clinical and commercial momentum. He highlights the recent pediatric trial initiation and prior positive Phase 3 data as key steps toward expanding Afrezza’s use into children and adolescents, which could materially enlarge its addressable market after a future FDA decision.

He also emphasizes that the newly revised dosing instructions should improve real‑world outcomes and facilitate switching from injections or pumps, supporting stronger uptake in both adult and younger patients. In parallel, he notes that MannKind is broadening its portfolio with Furoscix and preparing a targeted commercial strategy ahead of a 2026 regulatory decision, which together reinforce the company’s long‑term revenue growth potential.